Exchange: NASDAQ Sector: Financial Services Industry: Asset Management
0.06% $17.34
America/New_York / 18 apr 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 216.70 mill |
EPS: | 1.250 |
P/E: | 13.87 |
Earnings Date: | May 08, 2024 |
SharesOutstanding: | 12.50 mill |
Avg Daily Volume: | 0.0114 mill |
RATING 2024-04-18 |
---|
A |
Buy |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Buy | |
Return On Equity: | Sell | |
Return On Asset: | Strong Buy | |
DE: | Neutral | |
P/E: | Strong Buy | |
Price To Book: | Neutral |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt | n/a | n/a | n/a |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE 13.87 | sector: PE -18.15 |
PE RATIO: COMPANY / INDUSTRY |
---|
0x |
Company: PE 13.87 | industry: PE -47.59 |
DISCOUNTED CASH FLOW VALUE |
---|
$43.19 (149.09%) $25.85 |
Date: 2024-04-19 |
Expected Trading Range (DAY) |
---|
$ 16.83 - 17.85 ( +/- 2.94%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-01 | Dotter Laurie L. | Buy | 815 | Common Stock |
2024-04-01 | Albright Jerry | Buy | 815 | Common Stock |
2024-04-01 | Hatcher Robert K. | Buy | 815 | Common Stock |
2024-04-01 | Pennington Marcus Edward | Buy | 815 | Common Stock |
2024-04-01 | Pennington Marcus Edward | Buy | 1 051 | Common Stock |
INSIDER POWER |
---|
-2.58 |
Last 96 transactions |
Buy: 331 841 | Sell: 586 098 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 |
Volume Signals | |
---|---|
Price | $17.34 (0.06% ) |
Volume | 0.0034 mill |
Avg. Vol. | 0.0114 mill |
% of Avg. Vol | 29.37 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
SWK Holdings Corporation, a specialty finance company that focuses on the healthcare sector. It operates in two segments, Finance Receivables and Pharmaceutical Development. The company provides customized financing solutions to a range of life science companies, including companies in the biotechnology, medical device, medical diagnostics and related tools, animal health, and pharmaceutical industries, as well as institutions and inventors. It also offers non-discretionary investment advisory services to institutional clients in separately managed accounts to invest in life science finance. In addition, the company engages in the pharmaceutical development, formulation and manufacturing, and licensing business through the Peptelligence platform. Further, it intends to out-license its internal product pipeline to create novel formulations using its proprietary technology to develop treatments for patients and caregivers. The company was formerly known as Kana Software, Inc. and changed its name to SWK Holdings Corporation in December 2009. SWK Holdings Corporation was founded in 1996 and is headquartered in Dallas, Texas.